<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6589">
  <stage>Registered</stage>
  <submitdate>4/09/2016</submitdate>
  <approvaldate>4/09/2016</approvaldate>
  <nctid>NCT02895100</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis</studytitle>
    <scientifictitle>A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PTG-100-02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PTG-100
Treatment: drugs - Placebo group

Experimental: PTG-100 (150 mg QD) - Low dose

Experimental: PTG-100 (300 mg QD) - Medium dose

Experimental: PTG-100 (900 mg QD) - High dose

Placebo Comparator: Placebo group - Placebo control


Treatment: drugs: PTG-100
Daily dosing of PTG-100 by subject for a 12 week treatment period.

Treatment: drugs: Placebo group
Daily dosing of Placebo capsules by subject for a 12 week treatment period.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects receiving PTG-100 with clinical remission at Week 12 compared with placebo</outcome>
      <timepoint>12 week treatment period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of subjects with at least 1 adverse event (AE) comparing individual PTG-100 dosing groups with placebo - An adverse event is any undesirable experience associated with the use of a medical product in a patient.</outcome>
      <timepoint>Up to approximately 16 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with endoscopic response at Week 12 (defined as an endoscopic subscore of 0 or 1) - Mayo endoscopic subscore is one of the Mayo score components and its value ranges from 0 to 3 points</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with clinical response at Week 12 (defined as at least 1 point and 30% reduction from baseline in rectal bleeding and stool frequency subscores) - Mayo stool frequency and rectal bleeding subscores are two of the Mayo score components and each subscore value ranges from 0 to 3 points</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in endoscopy subscore from baseline to Week 12 - Mayo endoscopic subscore is one of the Mayo score components and its value ranges from 0 to 3 points</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in rectal bleeding and stool frequency subscores from baseline to Weeks 2, 4, 6, 8, 10, 12, and 16 - Mayo stool frequency and rectal bleeding subscores are two of the Mayo score components and each subscore value ranges from 0 to 3 points</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with endoscopic remission at Week 12 (defined as an endoscopic subscore of 0) - Mayo endoscopic subscore is one of the Mayo score components and its value ranges from 0 to 3 points</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Mayo Score from baseline to Week 12 - The Complete Mayo Score is the sum of 4 subscores (stool frequency, rectal bleeding, endoscopic findings, physician's global assessment. Each subscore ranges from 0 to 3, with the higher value indicating more severe disease. The total Complete Mayo Score ranges from 0 to 12.</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Partial Mayo Score from baseline to Weeks 2, 4, 6, 8, 12, and 16 - The Partial Mayo Score is the sum of 3 subscores (stool frequency, rectal bleeding, physician's global assessment. Each subscore ranges from 0 to 3, with the higher value indicating more severe disease. The Partial Mayo Score ranges from 0 to 9.</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in fecal calprotectin levels from baseline to Weeks 6 and 12 - Fecal calprotectin is used to detect inflammation in the intestines. For patients with ulcerative colitis (UC), it is a measure of the activity and severity of UC.</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline to Week 12 - IBDQ is a widely used questionnaire for health-related quality of life assessment in patients with inflammatory bowel diseases (IBDs)</outcome>
      <timepoint>12 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects developing antidrug antibodies (ADA) - ADA are antibodies which may develop as a result of an immunological reaction to a pharmaceutical agent. ADAs may inactivate the therapeutic effects of a drug and, in rare cases, cause adverse effects.</outcome>
      <timepoint>16 week study duration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency and type of adverse events (AE) (affecting = 5% of subjects) - An adverse event is any undesirable experience associated with the use of a medical product in a patient.</outcome>
      <timepoint>16 week study duration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria include:

          -  Male and female subjects age 18 to 80 years, inclusive

          -  Diagnosis of UC for at least 2 months prior to screening

          -  Moderate to severe active UC as defined by Mayo Score of 6 to 12 inclusive (range of
             0-12) at baseline with endoscopy score of at least 2 (range 0-3)

          -  Subject must have had an inadequate response, loss of response to or intolerance to at
             least of of the following medications: immunomodulators, TNF-alpha antagonists or
             corticosteroids

          -  Subject is unlikely to conceive, as defined by one of the following: a) subject is
             male, b) subject is surgically sterilized female, c) subject is post-menopausal female
             &gt;= 45 years of age with clinical documentation of menopause, or d) subject is woman of
             child bearing potential (WOCBP) and agrees to abstain from heterosexual activity, use
             adequate hormonal contraception or use double barrier contraception.

          -  For WOCBP, a negative pregnancy test at screening and within 24 hours of first dose of
             study medication</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria include:

          -  Subject has Crohn's Disease (CD), indeterminate colitis (IC) or presence or history of
             fistula with CD

          -  History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma;
             history or is at imminent risk of colectomy

          -  History or current evidence of colonic dysplasia or adenomatous colonic polyps

          -  Current bacterial or parasitic pathogenic enteric infection, including Clostridium
             difficile, infection with hepatitis B or C virus, infection with human
             immunodeficiency virus, infection requiring hospitalisation or intravenous
             antimicrobial therapy, or opportunistic infection within 6 months, any infection
             requiring antimicrobial therapy within 2 weeks, history of more than one episode of
             herpes zoster or any episode of disseminated zoster

          -  Live virus vaccination within one month prior to screening

          -  Subject has a concurrent clinically significant, unstable, or uncontrolled
             cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary,
             hematological, coagulation, immunological, endocrine/metabolic, or other medical
             disorder that, in the opinion of the investigator, might confound the study results or
             poses additional risk to the subject

          -  Known primary or secondary immunodeficiency

          -  History of myocardial infarction, unstable angina, transient ischaemic attack,
             decompensated heart failure requiring hospitalisation, congestive heart failure (NYHA
             Class 3 or 4), uncontrolled arrhythmias, cardiac revascularisation, stroke,
             uncontrolled hypertension, or uncontrolled diabetes within 6 months of screening

          -  Clinically meaningful laboratory abnormalities at screening

          -  Pregnant or lactating females

          -  Any surgical procedure requiring general anaesthesia within one month prior to
             screening, or planned elective surgery during the study

          -  History of malignant neoplasms or carcinoma in situ within 5 years prior to screening

          -  History of any major neurological disorders, as judged by the Investigator, or
             positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist

          -  Current or recent history of alcohol dependence or illicit drug use within 1 year
             prior to screening.

          -  Subject is mentally or legally incapacitated at the time of screening visit or has a
             history of clinically significant psychiatric disorders that would impact the
             subject's ability to participate in the trial according to the investigator

          -  Unable to attend study visits or comply with procedures

          -  Concurrent participation in any other interventional study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>240</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator # 908 - Herston</hospital>
    <hospital>Site Reference ID/Investigator # 900 - South Brisbane</hospital>
    <postcode>4006 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bosnia and Herzegovina</country>
      <state>Mostar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bosnia and Herzegovina</country>
      <state>Tuzla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Osijek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Split</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Nový Hradec Králové</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Zlín</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Eger</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kistarcsa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Mosonmagyaróvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Sopron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Newton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kielce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Ksawerów</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wloclawek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan'</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moskva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Rostov-na-Donu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Samara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ufa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Kragujevac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Zvezdara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Chernivtsi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ivano-Frankivs'k</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>L'viv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odessa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Uzhgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protagonist Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main objectives of this study are to evaluate the efficacy, safety, and tolerability of
      daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02895100</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bittoo Kanwar, MD</name>
      <address>Protagonist Therapeutics, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Calvert Lee</name>
      <address />
      <phone>(510) 474-0787</phone>
      <fax />
      <email>c.lee@ptgx-inc.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>